ABSTRACT In closed system models of fibrin formation, exosite-mediated thrombin binding to fibrin contributes to clot stability and is resistant to inhibition by antithrombin/heparin while still susceptible to small, active-site inhibitors. Each molecule of fibrin can bind~1.6 thrombin molecules at low-affinity binding sites (K d ¼ 2.8 mM) and~0.3 molecules of thrombin at high-affinity binding sites (K d ¼ 0.15 mM). The goal of this study is to assess the stability of fibrin-bound thrombin under venous flow conditions and to determine both its accessibility and susceptibility to inhibition. A parallel-plate flow chamber (7 Â 50 Â 0.25 mm) for studying the stability of thrombin (0-1400 nM) adhered to a fibrin matrix (0.1-0.4 mg/mL fibrinogen, 10 nM thrombin) under a variety of venous flow conditions was developed using the thrombin-specific, fluorogenic substrate SN-59 (100 mM). The flow within this system is laminar (R e < 1) and reaction rates are driven by enzyme kinetics (P e ¼ 100, D a ¼ 7000). A subpopulation of active thrombin remains stably adhered to a fibrin matrix over a range of venous shear rates (46-184 s
INTRODUCTION
Thrombin, the central enzyme of the coagulation process, binds to fibrin during clot formation, playing an important role in hemostasis by improving clot strength and stability (1) . Thrombin interacts with fibrin via two separate exosite-mediated interactions distinct from thrombin's active site (2): a low-affinity (K d,low z 2.8 mM) and abundant (1.6 thrombin molecules/fibrin monomer) binding site located between thrombin's anionic binding exosite 1 and the E-domain of fibrin (3) (4) (5) , and a high-affinity (K d,high z 0.15 mM) and relatively low abundance binding site (0.2-0.4 thrombin molecules/fibrin monomer) (4, 6) . This higher affinity binding site is complex, with a thrombin molecule binding to fibrin via both the E domain exosite 1 interaction, as well as second interaction between thrombin's anionic binding exosite 2 and the fibrin g 0 -chain-an alternative splice variant of the fibrin g-chain that accounts for~10% of the formed fibrin monomer (4, 5, 7, 8) . Together these binding interactions describe the conditions within a fibrin clot as consisting of a substantial stoichiometric excess of relatively low-affinity thrombin binding sites. Thus, while thrombin incorporated into the clot may only weakly interact with its initial binding site, it has the potential to undergo multiple binding events at alternative sites, effectively trapping thrombin within the fibrin clot.
Physiologic and pathologic roles of active clot bound thrombin have been proposed, which include the following: 1) localization of thrombin and clot propagation to the site of injury, thus minimizing coagulation downstream (9), 2) long-term stabilization and maintenance of clots independent of a new episode of tissue factor initiation (10) , and 3) thrombosis due to systemic dissemination of active thrombin if a clot structurally fails due to mechanical forces or is dismantled during fibrinolysis (11, 12) .
in which a subpopulation of fibrin-adhered thrombin is resistant to inhibition by antithrombin (AT) (11) , the primary thrombin inhibitor in vivo. This apparent resistance to AT inhibition of thrombin has been attributed to the high-affinity thrombin binding site that engages both of thrombin's anionic binding exosites in the presence of g 0 fibrin, which in occupying both of thrombin's exosites protects thrombin from AT inhibition (5, 11, 13, 14) . This resistance to AT inhibition is also maintained in the presence of unfractionated heparin (UFH), with suprapharmacological concentrations of UFH only achieving partial inhibition (11, (14) (15) (16) .
In addition to the resistance to inhibition by AT, the capacity of thrombin to remain bound to fibrin is implied by the current hypotheses concerning the physiologic role of clot-bound thrombin. Given the relatively weak binding affinities, a stable association is not obvious and empirical data directly addressing the mechanism of stability under flow is limited (17, 18) . In this study we believe we have developed, to our knowledge, a novel system in which to explore the behavior of fibrin-adhered thrombin in a flow reactor that recapitulates the shear rates observed in the venous system (19) . We present results examining the stability of fibrin-adhered thrombin as a function of shear rate, differing thrombin to fibrin molar ratios, and the susceptibility of fibrin-bound thrombin to inhibition by AT and AT þ UFH. The efficiency and stability of dabigatran, a smallmolecule active-site-directed inhibitor of thrombin (20) , is also assessed. To understand the structural features of the model system, we have employed scanning electron microscopy (SEM) and confocal microscopy to determine the fibrin structure. We have also constructed an in silico model of thrombin adhesion to a fibrin clot to delineate thrombin dynamics within the fibrin matrix. We believe that these model systems have the potential to advance our understanding of the role of clot-bound thrombin in pathologies associated with thrombosis and bleeding.
MATERIALS AND METHODS

Materials
Hirudin was purchased from Sekisui Diagnostics (Lexington, MA). The thrombin-specific fluorescent substrate, D-Val-Pro-Arg-6-amino-1-naphthalenesulfonamide-H-C 4 H 9 (SN-59), was received as a generous gift from Dr. S. Butenas (University of Vermont) (21, 22) . UFH and cystamine were purchased from Sigma-Aldrich (St. Louis, MO). Dabigatran was obtained from Alsachim (Illkirch-Graffenstaden, France).
Proteins
Fibrinogen (340 kDa, ε 0 280,1% ¼ 15.5) (23), thrombin (36.7 kDa, ε 0 280,1% ¼ 18.3) (24, 25) , and AT (58 kDa, ε 0 280,1% ¼ 6.2) (26) were prepared in-house from human plasma as previously described. Factor XIII in fibrinogen preparations was quantified using Zymutest factor XIII ELISA from HYPHEN BioMed (Neuville-Sur Oise, France) in conjunction with purified factor XIII (Haematologic Technologies; Essex Junction, VT). Fibrinogen conjugated to Alexa Fluor 647 was obtained from Molecular Probes (Eugene, OR).
Preparation of flow chamber
Flow chambers (50 Â 7 Â 0.25 mm) were manufactured in-house from polycarbonate ( Fig. S1 in the Supplemental Information). A removable polystyrene slide (Nunc, Rochester, NY) was attached to the bottom of the chamber using Flowable Sealant 734 from Dow Corning (Midland, MI) and allowed to cure overnight. Prepared flow chambers were plasmacleaned for 30 min in a PDC-3XG Plasma Cleaner (Harrick, Pleasantville, NY) with atmospheric gas.
Assembly of fibrin matrix in flow chambers
Fibrinogen (0.2 mg/mL, 200 mL) was converted to fibrin in the bottom of the flow chamber after incubation with thrombin (10 nM) for 1 min at room temperature (25 C) . The fibrin matrix was washed three times with 300 mL of HEPES-buffered saline (20 mM HEPES, 150 mM NaCl, pH 7.4; HBS) containing 0.1% PEG 8000 and 5 mM CaCl 2 (HBSP5). In some experiments the concentration of fibrinogen converted to fibrin was varied to 0.1 or 0.4 mg/mL, as noted.
Incorporation of exogenous thrombin into the fibrin matrix
After forming the fibrin matrix, exogenous thrombin (0-1400 nM, 400 mL) was incubated with the fibrin matrix for 15 min at room temperature (25 C) . After this incubation, the unadsorbed thrombin was removed and the flow chamber was washed three times with HBSP5 (300 mL). To determine that the exogenously added thrombin was stably incorporating into the fibrin matrix, this step was omitted in some experiments as noted.
Flow experiment procedure
The temperature (37 5 3 C) of the flow chamber during the experiments was maintained as described in Haynes et al. (27) . Flow rates were controlled using two NE-1000 syringe pumps from New Era Pump Systems (Farmingdale, NY) connected to the flow chamber using a four-way valve (Upchurch Scientific, Oak Harbor, WA) to simplify switching between different solutions as described in Haynes et al. (28) . The flow chamber was rinsed with HBSP5 for 5 min at a flow rate of 0.25 mL/min. A solution of SN-59 (100 mM) in HBSP5 was flowed over that chamber (0.2-0.8 mL/min; 46-184 s
À1
) and the effluent collected dropwise (~25 mL/drop) into HBSP5 containing 20 nM hirudin (75 mL). In some experiments, dabigatran (20 or 200 nM), antithrombin (0.15 mg/mL), or antithrombin plus UFH (4 U/mL) was added to the flowing solution of SN-59~10 min into the experiment. Approximately 10 min after the inhibitors were introduced to the flow chamber, they were removed from the flowing solution. The degree of SN-59 hydrolysis was determined using a Synergy 4 Fluorescence Plate Reader (BioTek Instruments, Winooski, VT) with an excitation wavelength of 350 nm and an emission wavelength of 470 nm. After each experiment, adsorbed thrombin was removed from the flow chamber by incubating the chamber in HBS containing 1% Triton X-100 (300 mL) for 15 min at room temperature before storage at À20 C for future analysis.
Ex-flow chamber determination of active fibrinadsorbed thrombin
Thrombin removed from flow chambers with Triton X-100 was reacted with SN-59 (100 mM) and the rate of SN-59 hydrolysis measured using a fluorescence plate reader (excitation wavelength of 350 nm; emission wavelength of 470 nm) at 37 C for 20 min or <20% substrate consumption, whichever came first. The rates of SN-59 hydrolysis were converted to thrombin concentrations using a standard curve.
Scanning electron microscopy
Thermanox coverslips (13 mm diameter, Nunc) were attached to the bottom of a six-well plate using Flowable Sealant 734 (Corning) and allowed to cure overnight. Fibrin was formed by incubating fibrinogen (0.2 or 2.5 mg/mL) with thrombin for 2 min at 25 C. The supernatant of the resulting reaction was removed and the coverslip washed three times with HBSP5 (500 mL). Fibrin clots were fixed as described in Storch et al. (29) , dehydrated in ethanol, critical point dried in liquid CO 2 , mounted, and Au/Pd sputter coated.
Confocal microscopy
Fibrin clots were formed in glass bottom microwell dishes (35 mm) from MatTak (Ashland, MA) by incubating Alexa Fluor 647-conjugated fibrinogen (0.2 mg/mL) with thrombin (10 nM) for 1 min at 25 C. The resulting fibrin was washed three times with HBSP5 (500 mL), visualized using a 510 META confocal laser scanning microscope (Zeiss MicroImaging, Thornwood, NY) with immersion oil. All images were acquired as 12-bit multitrack mode using appropriate laser excitation and emission filters as described in Brooks et al. (30) . The thickness of the fibrin matrix was determined using the Velocity software package from Perkin Elmer (Waltham, MA).
Analyses
Statistical analyses were performed using the Prism v6.07 software suite (GraphPad, La Jolla, CA). In some instances the flow-hydrolysis data were fit, as described in the literature (27, 28, 31, 32) , to Eq. 1 to simplify analysis:
where the concentration of product ([P]) at any given time (t) is expressed as the initial concentration of product ([P] 0 ), the concentration of product at steady state ([P] ss ), the turning point of the function (t 0 ), and the rate of change approaching steady state (t).
Characterization of flow
To characterize the flow within the chamber, the Reynold's number (R e ; the ratio of the inertial forces to the viscous forces), the Peclet number (P e ; the ratio of the inertial forces to substrate diffusion), and the Damkholer number (D a ; the ratio of the reaction rate to the diffusion rate), were defined as follows and their values are reported in Table 1 :
where U b is the bulk flow rate (assumed to be 0.4 mL/min in calculations), r is the density of the solvent, h is the height of the chamber, m is the viscosity of the solvent, D i is the diffusion coefficient of the substrate, k cat is the turnover number of the substrate by the enzyme (E), and K M is the Michaelis constant. The pertinent variables used in the calculations are defined in Table 1 . The small Reynold's number indicates that the flow is laminar, while the large Peclet and Damkholer numbers indicate that transport of substrate is dominated by flow convection and that the hydrolysis of substrate under these flow conditions is driven by the reaction rate (27, 33) . Finally, to assess whether our flow system is flow limited, an inverse Log-Log plot of flow rate verses product formation was fit to a linear regression for which a slope of À1 is indicative of a reaction-limited consumption of substrate under flow while a slope of À2/3 is indicative of a transportlimited reaction under flow (33, 34) .
Mathematical modeling of thrombin binding to fibrin
To model the binding of thrombin to both the high-and low-affinity sites on fibrin, the following reaction schemes were solved simultaneously using a Runga-Kutta algorithm that generates a time-dependent profile of all chemical species (35):
In these calculations, the K d values for both the high-and low-affinity thrombin binding sites as well as the number of binding sites are reported in Table 1 . The on-rates (k on ) for both the high-and low-affinity sites were assumed to be equal to each other at 10 6 M À1 s
À1
, to calculate the appropriate dissociation constants.
Modeling thrombin association to fibrin matrix
Using the parameters reported in Table 1 , thrombin adhesion to fibrin was modeled assuming the complete conversion of fibrinogen to fibrin after the addition of exogenous thrombin to the preformed fibrin clot. In some instances, the washing steps present in the empirical model were included in the in silico model as follows: To mimic washing in a closed system, unbound thrombin was assumed to be removed with the supernatant and the bound thrombin was allowed to reequilibrate between bound and free state in the new volume of wash buffer added (nominally 300 mL). To mimic washing under flow (5 min at 0.25 mL/min), the model system was allowed to reequilibrate in a 1500 mL volume using the methodology described above.
Modeling thrombin dissociation from fibrin matrix under flow
To model thrombin dissociation from the fibrin matrix, the free and bound concentrations of thrombin after the modeling of the association phase were concentrated within the volume of the flow chamber (87.5 mL) and allowed to equilibrate for 13 s, the time it nominally takes one chamber volume to pass through the flow chamber, under the assumption that a large time step can be used given the high Peclet number of the system and the limited anticipated roll of diffusion in regulating the kinetics of SN-59 hydrolysis by the fibrin-adhered thrombin. To model the removal of free thrombin from the system, the free thrombin concentration was reset to 0, 10, or 90% of that at the end of the previous iteration while the bound concentrations of thrombin were not altered to model thrombin flux from the fibrin matrix. The system was then allowed to reequilibrate, assuming the new concentration of free thrombin.
RESULTS
Characterization of fibrinogen preparation and fibrin structure
The preparation of fibrinogen used in these studies contained factor XIII(a) at a ratio of 0.89 pmol/nmol fibrinogen. The structure of fibrin fibers formed from an initial physiologic fibrinogen concentration (2.5 mg/mL) or at the concentration of fibrinogen used in these studies (0.2 mg/mL) is similar ( Fig. 1, A and B). The thickness of the fibrin matrix formed using 0.2 mg/mL Alexa Fluor-conjugated fibrinogen and 10 nM thrombin, as determined using confocal microscopy (n ¼ 5), ranges from 0.20 5 0.1 to 2.4 5 1.3 mm with an average thickness of 0.52 5 0.04 mm (mean 5 SD). A representative image of the fibrin coverage is shown in Fig. 1 C. The deposited fibrin consists of both two-dimensional fibers, as well as more gel-like regions that appear punctate in Fig. 1 C. These observations are consistent with previous studies of fibrin structure as a function of initial fibrinogen concentration (34).
Incorporation of exogenous thrombin into the preformed fibrin matrix
A key element of this study is the notion that exogenously added thrombin can be stably incorporated into a preformed fibrin matrix. Fig. 2 A compares SN-59 hydrolysis (100 mM) under flow (92 s À1 ) after the incubation of a preformed fibrin matrix with 80 pmol (200 nM), 560 pmol (1400 nM), or no additional thrombin for 15 min at 25 C. The progress curves consist of three regions (see Eq. 1), as follows:
1) an initial region where the buffer without substrate is exiting the flow chamber; 2) a region of sharply increasing fluorescence signal consistent with substrate being hydrolyzed as it enters the flow chamber; and 3) a steady-state plateau region, which indicates that the catalyst concentration in the flow chamber is not declining during the observation period (27, 28, 31, 32) .
In the absence of exogenously added thrombin, a lower level of SN-59 hydrolysis was observed, reflecting the presence of residual thrombin used to catalyze the formation of the fibrin matrix. After preincubation of the fibrin matrix with exogenous thrombin, the steady-state level of SN-59 hydrolysis achieved increased and appeared to be dependent on the loading concentration of thrombin. These data demonstrate that thrombin can be incorporated into a fibrin clot after initial clot formation. It is also of note that at the highest concentration of exogenously added thrombin (1400 nM), there is an apparent decrease in the fluorescence intensity once a steady state of hydrolysis has been reached. This is potentially due to increased competition between thrombin molecules for binding sites near the interface of the fibrin matrix and the bulk flow.
Clot-bound thrombin activity as a function of exogenous adsorbed thrombin concentration
The concentration of exogenously added thrombin, allowed to be adsorbed to the clot (formed from an initial fibrinogen concentration of 0.2 mg/mL), was titrated from 50 to 1400 nM and a thrombin binding isotherm was constructed (Fig. 2 B) . Steady-state fluorescence intensity was converted to thrombin concentration by assuming that a single drop (~25 mL) of effluent takes 3.7 s (at 92 s À1 ) to pass through the flow chamber. A rate of SN-59 hydrolysis was obtained by dividing the steady-state fluorescence level (obtained by fitting the experimental curves to Eq. 1) by this transit time and converted to a thrombin concentration using a standard curve. Thrombin binding appeared saturable under these conditions, reaching a maximum of~35 nM at loading concentrations >500 nM.
Using an in silico model of thrombin-fibrin interactions, a theoretical thrombin binding isotherm was constructed reflecting load concentrations of thrombin ranging from 50 to 1400 nM and the fixed fibrinogen/fibrin concentration used in the empirical experiment above (Fig. 2 B) . The modeling approach takes into account the effect of the washing steps in the empirical protocol (three washes with 300 mL HBSP5 followed by a reequilibration in a volume of 1500 mL to represent the washing of the system under flow) that progressively reset the equilibrium distribution between free and fibrin-bound thrombin. Calculated in this way, the theoretical binding isotherm shows close correspondence with the empirical results. In contrast, a theoretical binding isotherm for thrombin association with fibrin-reflecting dynamics in the absence of the washing steps in the empirical protocol (see Fig. 2 B, inset) predicts much more fibrin-bound thrombin.
Clot-bound thrombin activity as a function of the number of potential thrombin binding sites
To see if varying the number of potential binding sites would alter the hydrolysis rate of SN-59 by fibrin-adhered thrombin, the concentration of fibrinogen used to form the initial fibrin matrix was varied from 0.1 to 0.4 mg/mL, while the loading concentration of thrombin 200 nM (80 pmol) was held constant (Fig. 3 A) . Increasing the potential number of thrombin binding sites approximately fourfold resulted in an approximate twofold increase in the steadystate fluorescence intensity resulting from SN-59 hydrolysis. The steady-state levels of bound thrombin ranged from 4 to 7.2 pmol or 5 to 9% of the thrombin loading concentration ( Table 2 ). The difference in maximum fluorescence intensity when comparing 0.1 mg/mL of fibrinogen to 0.4 mg/mL fibrinogen is statistically significant (p ¼ 0.05) (Fig. 3 B) , but the fluorescence signal appears to be relatively unstable at the highest initial fibrinogen concentration tested (0.4 mg/mL; Fig. 3 A) . Given the relatively thin nature of the fibrin matrix formed by 0.2 mg/mL fibrinogen in this study (Fig. 1 C) , the results are consistent with limited diffusion of the substrate through the gel-like regions, reaction dynamics at the interface of the fibrinadhered thrombin surface, and the bulk flow dominating the observed kinetics under flow.
Using our in silico model with the inclusion of the washes from the experimental protocol, we calculated the percent of thrombin potentially bound to fibrin for the three concentrations of fibrinogen and fixed thrombin load (80 pmol, 200 nM) used in the empirical experiments. The calculations were based on the assumption that all of the fibrinogen used is converted to fibrin and that there are two classes of thrombin binding sites with respective affinities and number of sites per fibrin monomer values reported in Table 1 . The analysis yielded the number of low-affinity thrombin binding sites (96, 192, or 384 pmol) and corresponding highaffinity sites (18, 36, or 72 pmol) available at each fibrinogen concentration. The predicted percentage of the loading thrombin that would be bound to the fibrin matrix was 0.3, 2.1, and 3.1% for 0.1, 0.2, and 0.4 mg/mL fibrinogen, respectively.
Activity of clot-bound thrombin as a function of shear rate
When the shear rate of the system was varied from 46 to 184 s À1 , there was an apparent decrease in steady-state hydrolysis of SN-59 (Fig. 4) , consistent with decreased passage time of a given volume of substrate through the catalytically active flow chamber. To verify that this was due to the reaction being limited by the rate of SN-59 hydrolysis by fibrin-adhered thrombin, the flow rate versus steady-state fluorescence level were plotted as a double reciprocal log plot (Fig. 4, inset) . The slope of a linear regression of this plot was À1.0 5 0.1, consistent with a reaction-limited system (33, 34) in which reaction kinetics dominate the observed chemistry and not fluid dynamics, meaning that the observed fluorescence intensity at steady state scales linearly with decreasing shear rate.
Recovery and quantitation of fibrin-adhered thrombin from flow chambers
Active thrombin was recovered from the flow chambers after treatment with 1% Triton X-100. The amount of active thrombin recovered showed a strong correlation with the observed steady-state fluorescence intensities (R 2 ¼ 0.6346, p < 0.001) as illustrated in Fig. 5 . However, the amount of thrombin recovered was one-half that expected from the observed steady-state fluorescence intensities (Table 2) . One potential explanation for this difference could be FXIIIa-dependent cross linking of thrombin to fibrin. However, pretreatment of the fibrinogen with cystamine (1 mM) (36) or immunodepleting it of FXIII (23) did not result in a decrease in steady-state fluorescence intensity (data not shown), suggesting the stable binding of the thrombin to fibrinogen in the presence of 1% Triton X-100 is not the result of covalent cross linking of the two proteins. Consistent with this, a proteomics-based analysis of fibrin-bound plasma proteins did not detect covalently linked thrombin (37), confirming previous biochemical reports (6, 38) .
Susceptibility of clot-bound thrombin under flow to inhibition by AT and UFH
The susceptibility of clot-bound thrombin to AT inhibition was assessed in the presence and absence of UFH (Fig. 6 A) .
In these experiments, a solution of SN-59 (100 mM) was flowed through the chamber for 10 min, a period of time sufficient to achieve a stable fluorescence signal, followed by a solution containing SN-59 (100 mM) þ AT (2.6 mM) or SN-59 (100 mM) þ AT (2.6 mM) þ UFH (4 U/mL). After 10 min, a flowing solution containing only SN-59 in HBSP5 was reapplied and the fluorescence signal monitored for an additional 10 min. In the control, SN-59 in HBSP5 was flowed continuously for 30 min. In the presence of AT alone, a net decline in the fluorescence signal of~22% relative to the control was observed, with no recovery in fluorescence signal after removal of AT from the flowing phase. In the presence of AT and UFH a stable net decrease in fluorescence intensity of 74% was observed, similar to results from closed system experiments (11), suggesting that exogenously added thrombin behaves similarly to that which is formed in situ.
To interpret the extent to which these data support the idea that clot-bound thrombin is protected from AT inhibition, the degree to which the presence of AN-59 would protect AT from inhibition in the absence of fibrin was assessed. Second-order rate constants reported for the inhibition of thrombin by AT range from 7000 to 10,000 M À1 s À1 (39) (40) (41) , which are increased 1000-fold in the presence of UFH (40) .When the reaction kinetics between thrombin and AT were assessed in the presence of 100 mM SN-59, an apparent second-order rate constant of 1600 M À1 s À1 was determined, with UFH (4 U/mL) again accelerating the reaction 1000-fold.Thus the presence of 100 mM SN-59, in the absence of UFH and fibrin, prolongs the half-life of thrombin in the presence of AT (2.6 mM) from~38 to~166 s; however, this reduction in the inhibition kinetics would still result in 90% of the thrombin being inhibited in <600 s in the absence of UFH and fibrin and complete inhibition in the presence of UFH if the reaction kinetics were not additionally altered by the presence of fibrin. Based on a net change in thrombin activity of only 22% in 10 min (Fig. 6 A) , the association of thrombin with a fibrin clot appears to reduce the second-order rate constant for AT reaction with thrombin to~1/10th that measured in the presence of SN-59 without fibrin. The persistence of~25% of fibrin-associated thrombin over the same time frame in the presence of UFH supports the existence of at least two subpopulations of thrombin with greatly differing susceptibility to AT inhibition (5,13).
Inhibition of clot-bound thrombin by dabigatran
Unlike AT (5UFH), dabigatran is a small-molecule thrombin inhibitor that does not require access to thrombin's exosites to perform its anticoagulant function. Thus, as would be predicted, it is able to reversibly inhibit nearly all of the observed thrombin activity (Fig. 6 B) in experiments analogous to those described above for inhibition by AT (5UFH) (11, 14) . Note the rapid recovery in active thrombin after removal of dabigatran from the reaction mixture. In the presence of 20 and 200 nM dabigatran, 87 and 66% of the initial fluorescence intensity was recovered, respectively, within 600 s.
Theoretical model of thrombin binding and dissociation to a fibrin matrix
The empirical protocols used in this study result in a fibrin matrix populated with thrombin molecules that are resistant to removal under flow conditions. For example, at a shear FIGURE 6 Inhibition of clot-bound thrombin by AT-UFH and dabigatran. Fibrin was formed by incubating fibrinogen (0.2 mg/mL) with thrombin (10 nM) for 1 min at 25 C and an additional 80 pmol of exogenous thrombin was incorporated into the fibrin matrix by incubating for 15 min at 25 C. (A) SN-59 (100 mM) was flowed (92 s
À1
) through the chamber and allowed to establish equilibrium for~10 min. AT (2.6 mM; dark shaded) or AT with heparin (4 U/mL, light shaded) was added to the flowing SN-59 solution (first arrow). After an additional 10 min, the AT or AT with heparin was removed from the flowing solution (second arrow) and allowed to reequilibrate for 10 min. (B) In analogous experiments to those in (A), dabigatran (20 nM, dark shaded; 200 nM, light shaded) was introduced to the system. All data are presented as the mean 5 SE (n ¼ 3). The solid trace is reproduced from Fig. 2 and corresponds to the reaction in the absence of either AT (5UFH) or dabigatran. rate of 92 s À1 , the solvent volume over the fibrin surface is exchanged~140 times in the 30 min while displaying stable levels of SN-59 hydrolysis. This is the population that remains after the initial washing steps and represents only a fraction of the applied thrombin load (for example, see Fig. 2 B or Table 2 ). Fig. 7 represents a theoretical analysis aimed at elucidating the partitioning of thrombin between the two classes of binding sites and the solution phase during the initial loading step and under a stepwise simulation of flow.
The adsorption of thrombin to the fibrin matrix (Fig. 7 A) can best be described as occurring in two stages: an initial stage in which the free thrombin primarily binds to the numerous low-affinity thrombin binding sites followed by a redistribution phase in which the fibrin-associated thrombin population shifts toward the high-affinity thrombin binding sites. Fig. 7 B models the dissociation of thrombin from the fibrin when the fibrin-bound thrombin is compressed into the volume of the flow chamber (87.5 mL) and the free thrombin concentration is set to zero. The assumption here is that the binding sites are distributed throughout the entire volume, rather than spatially segregated at the surface. Thrombin initially dissociates primarily from the low-affinity thrombin binding sites. This is followed by slow reequilibration in which some of the sites become repopulated from the pool of thrombin associated with the high-affinity thrombin binding sites. In Fig. 7, C-E , the dissociation process is repeatedly iterated (23 times) in a discontinuous approximation of continuous flow. The simulations differ in the percent of free thrombin retained with each iterations, i.e., the percent of free thrombin trapped in the fibrin matrix with the bound thrombin, as opposed to free thrombin in bulk solution that is removed before the next reequilibration. When 0 or 10% of the free thrombin is retained in each iteration (Fig. 7, C  and D) , this model does not recapitulate the observed thrombin stability in our experimental system; however, when 90% of the free thrombin is retained, the stability of the system is greatly enhanced and approaches our experimental observations (Fig. 7 E) . In all three cases, the thrombin bound to the high-affinity thrombin binding sites is essentially serving as a pool from which the low-affinity thrombin-binding sites can become repopulated.
To account for the required trapping of thrombin within the fibrin matrix predicted above, the discontinuous approximation was recalculated with the assumption that the volume occupied by the fibrin matrix was~1 mL. This volume of fibrin would correspond to a height of the fibrin matrix of 2.9 mm, which is consistent with the maximum measured height of the fibrin matrix of 2.4 5 1.3 mm. When the binding sites are spatially segregated to this extent, <0.1% of the thrombin is free at any point. Of this small percentage of thrombin, only a subset will diffuse into the flowing solution and be removed from the system FIGURE 7 Models of both thrombin association and dissociation from the fibrin matrix reveal the dynamics of thrombin binding within a clot. (A) Thrombin binding to fibrin. Exogenous thrombin (200 nM) binding to the fibrin matrix was modeled as described in Materials and Methods assuming a total volume of 400 mL and the complete conversion of fibrinogen (0.2 mg/mL) to fibrin. Free thrombin (C) binds primarily to low-affinity thrombin binding sites (;) but redistributes to high-affinity thrombin binding sites (:) until equilibrium is reached. (B) Dissociation of thrombin from fibrin. The dissociation of thrombin was modeled using the equilibrium binding site occupations calculated in (A), in the absence of free thrombin except in the volume of the flow chamber (87.5 mL). The initial burst in free thrombin (C) is a result of thrombin dissociation from low-affinity thrombin binding sites (;). This is followed by a slower partial repopulation of the low-affinity sites from the thrombin occupied high-affinity binding sites (:). (C-E) Stepwise dissociation of thrombin from fibrin. The calculation shown in (B) was repeated after allowing the system to come to equilibrium for 13 s (flow cell volume passage time at 92 s À1 ) and resetting the free thrombin with each iteration. The majority of fibrin-bound thrombin is associated with high-affinity thrombin binding sites (:) as illustrated in Fig. 7 E. Together, therefore, these mechanisms allow fibrin-adhered thrombin to be sequestered within a clot.
DISCUSSION
In this study we present, to the best of our knowledge, novel models for the behavior of fibrin-bound thrombin under venous flow conditions using purified proteins in which a fibrin matrix was formed and exogenous thrombin was allowed to bind to the fibrin matrix. The accessibility, activity, and stability of the adhered thrombin was evaluated by flowing the fluorogenic, thrombin-specific substrate SN-59 through the flow chamber and measuring changes in substrate hydrolysis in the effluent. The data obtained in this study permit us to examine our models in the context of preexisting experiments and gain insight into the dynamic nature of clot-bound thrombin.
In our chamber, laminar flow should be fully developed and the hydrolysis of the SN-59 substrate driven by reaction kinetics and bulk flow dynamics, not diffusion of the substrate to the catalytically active surface. The pore size in the fibrin matrix ( Fig. 1) should be sufficient for both thrombin and AT, and the SN-59 substrate, to diffuse within the fibrin matrix. These predictions were substantiated when the shear rate was varied over a range of known venous shear rates (eightfold difference) and no diffusional effects limiting substrate hydrolysis were observed (Fig. 4) . The amount of exogenous thrombin adsorbed and retained within the fibrin matrix is in agreement with that predicted by our theoretical thrombin binding isotherm. We interpret these results as implying that all of the thrombin adhered to the fibrin matrix is active and accessible to the SN-59 substrate in the flowing solution.
Of particular note in this study is the remarkable stability of fibrin-adhered thrombin when exposed to shear rates equivalent to those of the venous system for upwards of 30 min. This is particularly impressive, given the relatively low affinity that has been reported for the thrombin-fibrin complex even when the increased stability granted by the g 0 splice variant is taken into account. Our stepwise computational model of thrombin removal (Fig. 7 , C-E) predicts that thrombin should not remain stably bound to fibrin, even with an abundance of potential binding sites, if free thrombin is not sequestered within the fibrin matrix. When free thrombin remains within the fibrin matrix and does not exchange with the bulk solution, the apparent dissociation constants are decreased. We attribute this reequilibration of thrombin within the fibrin clot to the remarkable stability observed when exogenously added thrombin is incorporated into the clot. This conclusion is in line with the recent work of Zhu et al. (18) in which they showed that >85% of the thrombin formed during tissue factor-initiated whole-blood coagulation under flow (200 s À1 ) is retained by the fibrin fibers.
An important caveat of our model of clot-bound thrombin is the absence of platelets and other blood cells that would become trapped within a clot. The entrapment of cells, namely platelets and erythrocytes, within a clot results in a notable decrease in fibrin clot permeability (42) , ultimately resulting in hindered transport of procoagulant species, including thrombin, within the clot itself (43) (44) (45) . Furthermore, in vivo and in vitro models of whole blood clot formation suggest that clot-bound thrombin is trapped within the core of a growing thrombus and its ability to diffuse within the fibrin clot is limited by the incorporation of platelets into the thrombus (46) (47) (48) . The recent work of Muthard et al. (17) demonstrates that under arterial flow conditions (2000 s À1 ) more thrombin and fibrin are incorporated into a growing thrombus in addition to platelets, thus generating a denser clot in which thrombin in trapped in small pockets and not able to diffuse freely. Consequently when clots, under venous and arterial flow conditions, were formed in the presence of an anti-g 0 antibody, the only significant impact was under venous flow conditions (100 s À1 ) where the antibody resulted in larger clots with thrombin distributed over a greater area. In light of our models, we can extend biochemical insight into this observed behavior. The high-affinity thrombin binding site involving g 0 -fibrin does not serve as a reserve of clot-bound thrombin in arterial clots due to reduced clot permeability; however, in less dense venous clots it does aid in sequestering the thrombin and limiting diffusion throughout the clot.
Although the thrombin binding site on g 0 -fibrin protects thrombin from inhibition by AT-UFH (13), it is important to consider the microenvironment in which these sites present themselves. In a low-density clot with relatively high permeability, our computational model would predict that if there are sufficient low-affinity thrombin binding sites surrounding a high-affinity site that there would be a strong likelihood that thrombin molecule would be redistributed from a high-affinity to a low-affinity binding site. Our modeling shows the majority of the fibrinassociated thrombin during equilibrium is bound to high-affinity thrombin binding sites; however, conventional wisdom suggests that these sites are protected from inhibition by AT-UFH (5, 13) . If this is in fact the case, the only way that AT-UFH can inhibit these thrombin molecules is if they are continually shifting between low-and high-affinity thrombin binding sites. The density and permeability of a clot will also influence the function and efficacy of both heparin and dabigatran when used as anticoagulant therapies. In a highly permeable clot, such as that formed in our empirical model, one would expect more rapid and more complete inhibition by the AT-UFH complex than in the presence of a more densely formed clot, such as those formed in the arterial system, consistent with previous observations in closed system experiments (11) .
A similar redistribution of thrombin between high-and low-affinity binding sites is also important to take into consideration when interpreting hemostatic assays. Of particular note is the calibrated automated thrombogram in which clots formed in platelet-free plasma exhibit greater thrombin generation than those formed in platelet-rich plasma (49)-a contributing factor to which may be the entrapment of thrombin within the platelet-rich fibrin clot. Likewise, in minimally altered whole blood models of coagulation (50, 51) , the thrombin-AT complex that is measured in the serum often accounts for~50% of the plasma prothrombin being converted to thrombin. Presumably, within the clot, there is also a population of thrombin that is resistant to inhibition and additionally protected by the platelets incorporated into the clot.
B€ anninger et al. (52) reported that fibrin formed in the presence of higher thrombin concentrations was better able to retain thrombin as presumably the higher-quality fibrin was able to provide more total thrombin binding sites between which the thrombin molecules could redistribute. Lower-quality fibrin, formed with less thrombin, had greater porosity, thus permitting thrombin to more readily dissociate-partially explaining the instability of clots formed in hemophiliacs. This also implies that the quality of a fibrin clot is directly related to the ability of the dabigatran-thrombin complex to be retained within the clot. Higher-quality, denser clots will likely sequester more dabigatran-thrombin complex even after the cessation of treatment, while lower-quality clots will be more susceptible to rebound phenomena as thrombin would more readily dissociate. This intrinsically presents a ''Catch-22'' as dabigatran inhibits thrombin-the very enzyme needed to assure its own stability. In turn, this may explain the variability in rebound phenomena that have been observed after cessation of dabigatran treatment (20) .
In conclusion, this study presents an innovative model of clot-bound thrombin under venous flow conditions that provides biochemical insights into the dynamic nature of clotbound thrombin. Clot-bound thrombin is a potent pool of enzymatic activity and the ability to manipulate it may have important implications in the improvement of existing therapeutics and in the development of novel therapeutics to treat both thrombosis and bleeding.
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